Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
出版年份 2021 全文链接
标题
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-09-21
DOI
10.1016/j.annonc.2021.09.005
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS)
- (2021) P.G. Casali et al. ANNALS OF ONCOLOGY
- Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib
- (2020) Alessandro Gronchi et al. JAMA Surgery
- Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’
- (2020) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2020) Jean-Yves Blay et al. LANCET ONCOLOGY
- Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
- (2020) Michael C Heinrich et al. LANCET ONCOLOGY
- Imaging surveillance of gastrointestinal stromal tumour: current recommendation by National Comprehensive Cancer Network and European Society of Medical Oncology-European Reference Network for rare adult solid cancers
- (2019) F. Alessandrino et al. CLINICAL RADIOLOGY
- Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study
- (2018) Toto Hølmebakk et al. ANNALS OF SURGICAL ONCOLOGY
- Genotype and risk of tumour rupture in gastrointestinal stromal tumour
- (2018) K. Boye et al. BRITISH JOURNAL OF SURGERY
- Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era
- (2018) W. T. A. van der Graaf et al. BRITISH JOURNAL OF SURGERY
- Familial PDGFRA -mutation syndrome: somatic and gastrointestinal phenotype
- (2018) Paul N. Manley et al. HUMAN PATHOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
- (2018) J Mateo et al. ANNALS OF ONCOLOGY
- Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour
- (2017) Lorenzo D'Ambrosio et al. EUROPEAN JOURNAL OF CANCER
- Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib
- (2017) Heikki Joensuu et al. JAMA Oncology
- Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine
- (2016) T. Hølmebakk et al. BRITISH JOURNAL OF SURGERY
- Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies
- (2016) Kjetil Søreide et al. Cancer Epidemiology
- Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial
- (2016) Heikki Joensuu et al. JOURNAL OF CLINICAL ONCOLOGY
- Transcriptome sequencing identifiesETV6-NTRK3as a gene fusion involved in GIST
- (2016) Monica Brenca et al. JOURNAL OF PATHOLOGY
- Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
- (2016) Olivier Mir et al. LANCET ONCOLOGY
- KIT, PDGFRA, and BRAF Mutational Spectrum Impacts on the Natural History of Imatinib-naive Localized GIST
- (2015) Sabrina Rossi et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery
- (2015) H. Joensuu et al. EUROPEAN JOURNAL OF CANCER
- BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance
- (2015) Gerald S. Falchook et al. Oncotarget
- Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST
- (2014) A. Wozniak et al. CLINICAL CANCER RESEARCH
- Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib – Analysis of prognostic factors (EORTC-STBSG collaborative study)
- (2014) S. Bauer et al. EJSO
- Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in China
- (2014) Chun-Yan Du et al. EUROPEAN JOURNAL OF CANCER
- Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial
- (2014) Christopher L. Corless et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience
- (2013) Piotr Rutkowski et al. ANNALS OF SURGICAL ONCOLOGY
- Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
- (2013) Yoon-Koo Kang et al. LANCET ONCOLOGY
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Natural History of Imatinib-naive GISTs
- (2011) Sabrina Rossi et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132
- (2011) Dian Wang et al. ANNALS OF SURGICAL ONCOLOGY
- Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts
- (2011) Heikki Joensuu et al. LANCET ONCOLOGY
- Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour
- (2010) P. Hohenberger et al. BRITISH JOURNAL OF SURGERY
- DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours
- (2010) Marco Novelli et al. HISTOPATHOLOGY
- Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients
- (2010) JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
- (2010) Axel Le Cesne et al. LANCET ONCOLOGY
- SDHB immunohistochemistry: a useful tool in the diagnosis of Carney–Stratakis and Carney triad gastrointestinal stromal tumors
- (2010) José Gaal et al. MODERN PATHOLOGY
- Gastric Stromal Tumors in Carney Triad Are Different Clinically, Pathologically, and Behaviorally From Sporadic Gastric Gastrointestinal Stromal Tumors: Findings in 104 Cases
- (2009) Lizhi Zhang et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?
- (2009) C. Mussi et al. ANNALS OF ONCOLOGY
- Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS)
- (2009) Alessandro Gronchi et al. EUROPEAN JOURNAL OF CANCER
- Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
- (2009) S. George et al. EUROPEAN JOURNAL OF CANCER
- Pediatric Gastrointestinal Stromal Tumors
- (2009) Alberto S. Pappo et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial
- (2009) Axel Le Cesne et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
- (2009) Ronald P DeMatteo et al. LANCET
- Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis
- (2009) Jason S Gold et al. LANCET ONCOLOGY
- Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib
- (2009) Katherine A. Janeway et al. PEDIATRIC BLOOD & CANCER
- Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665
- (2008) Burton L. Eisenberg et al. JOURNAL OF SURGICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started